SCPH — Scpharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $164.41m
- $127.21m
- $13.59m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.42 | ||
| Price to Tang. Book | 4.42 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12.1 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -68.1% | ||
| Return on Equity | -99.97% | ||
| Operating Margin | -407.53% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 13.59 | 40.01 | 97.75 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Directors
- Jack Khattar NEC (59)
- John Tucker PRE (58)
- Rachael Nokes SVF (46)
- William Abraham IND (61)
- Mette Agger IND (56)
- Minnie Baylor-Henry IND (73)
- Sara Bonstein IND (40)
- Frederick Hudson IND (75)
- Leonard Schaeffer IND (75)
- Klaus Veitinger IND (59)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 19th, 2013
- Public Since
- November 17th, 2017
- No. of Shareholders
- 23
- No. of Employees
- 135
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 36,054,409
- Address
- 25 Burlington Mall Road, Suite 203, BURLINGTON, 01803
- Web
- https://www.scpharmaceuticals.com/
- Phone
- +1 6175170730
- Contact
- Katherine Taudvin
- Auditors
- RSM US LLP
Upcoming Events for SCPH
scPharmaceuticals Inc Annual Shareholders Meeting
scPharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 scPharmaceuticals Inc Earnings Release
Similar to SCPH
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
FAQ
What is the Scpharmaceuticals share price?
As of Today at 19:19 UTC, shares in Scpharmaceuticals are trading at $4.56. This share price information is delayed by 15 minutes.
How has the Scpharmaceuticals share price performed this year?
Shares in Scpharmaceuticals last closed at $4.56 and the price had moved by -54.31% over the past 365 days. In terms of relative price strength the Scpharmaceuticals share price has underperformed the S&P500 Index by -61.98% over the past year.
What are the analyst and broker recommendations for Scpharmaceuticals?
The overall consensus recommendation for Scpharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Scpharmaceuticals dividend yield?
Scpharmaceuticals does not currently pay a dividend.
Does Scpharmaceuticals pay a dividend?
Scpharmaceuticals does not currently pay a dividend.
When does Scpharmaceuticals next pay dividends?
Scpharmaceuticals does not currently pay a dividend.
How do I buy Scpharmaceuticals shares?
To buy shares in Scpharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Scpharmaceuticals?
As of the previous close price of $4.56, shares in Scpharmaceuticals had a market capitalisation of $164.41m.
Where are Scpharmaceuticals shares listed?
Here are the trading details for Scpharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SCPH
What kind of share is Scpharmaceuticals?
Based on an overall assessment of its quality, value and momentum Scpharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Scpharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Scpharmaceuticals is $19.50. That is 327.63% above the last closing price of $4.56.
Analysts covering Scpharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.48 for the next financial year.
What is the trend in the Scpharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Scpharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -31.96%.
As of the last closing price of $4.56, shares in Scpharmaceuticals were trading -27.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Scpharmaceuticals PE Ratio?
The Scpharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Scpharmaceuticals?
Scpharmaceuticals' management team is headed by:
- Jack Khattar - NEC
- John Tucker - PRE
- Rachael Nokes - SVF
- William Abraham - IND
- Mette Agger - IND
- Minnie Baylor-Henry - IND
- Sara Bonstein - IND
- Frederick Hudson - IND
- Leonard Schaeffer - IND
- Klaus Veitinger - IND